Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Inclusion Criteria: * Patient is ≥ 18 years of age on the day of signing informed consent. * Candidate for ipilimumab and nivolumab therapy for metastatic renal cancer per the treating physician investigator. * Patient has a performance status of ≤ 2 on the Zubrod performance scale. * Patient has a histological or cytological diagnosis of renal cancer with clear cell or sarcomatoid component. * Radiologic or clinical evidence of metastatic disease, or progressive locally advanced disease. * Absolute neutrophil count ≥ 1,500/uL. * Platelets ≥ 75K/μL. * Hemoglobin ≥ 8.5 g/dL. * Calculated creatinine clearance is ≥ 30 ml/min as per the Cockroft-Gault formula. * Direct bilirubin ≤ 1.5 x upper limit of normal (ULN) OR total bilirubin levels ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5 ULN. * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x ULN except for patients with liver metastases, AST/ALT should be ≤ 5 x ULN. * Patient received no prior systemic anti-cancer therapy for metastatic disease. * Patient has evaluable or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Bone metastases, pleural effusion or ascites will be considered evaluable disease sites. * Tumor mass: Must be accurately measurable in at least 1 dimension (longest diameter to be recorded) with a minimum size of: * 10 mm by CT scan (CT scan slice thickness no greater than 5 mm, Or: * 20 mm by chest X-…